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Abstract
Background: Clinicopathological studies suggest that Alzheimer’s disease (AD) pathology begins ,10–15 years before the
resulting cognitive impairment draws medical attention. Biomarkers that can detect AD pathology in its early stages and
predict dementia onset would, therefore, be invaluable for patient care and efficient clinical trial design. We utilized a
targeted proteomics approach to discover novel cerebrospinal fluid (CSF) biomarkers that can augment the diagnostic and
prognostic accuracy of current leading CSF biomarkers (Ab42, tau, p-tau181).
Methods and Findings: Using a multiplexed Luminex platform, 190 analytes were measured in 333 CSF samples from
cognitively normal (Clinical Dementia Rating [CDR] 0), very mildly demented (CDR 0.5), and mildly demented (CDR 1)
individuals. Mean levels of 37 analytes (12 after Bonferroni correction) were found to differ between CDR 0 and CDR.0
groups. Receiver-operating characteristic curve analyses revealed that small combinations of a subset of these markers
(cystatin C, VEGF, TRAIL-R3, PAI-1, PP, NT-proBNP, MMP-10, MIF, GRO-a, fibrinogen, FAS, eotaxin-3) enhanced the ability of
the best-performing established CSF biomarker, the tau/Ab42 ratio, to discriminate CDR.0 from CDR 0 individuals. Multiple
machine learning algorithms likewise showed that the novel biomarker panels improved the diagnostic performance of the
current leading biomarkers. Importantly, most of the markers that best discriminated CDR 0 from CDR.0 individuals in the
more targeted ROC analyses were also identified as top predictors in the machine learning models, reconfirming their
potential as biomarkers for early-stage AD. Cox proportional hazards models demonstrated that an optimal panel of
markers for predicting risk of developing cognitive impairment (CDR 0 to CDR.0 conversion) consisted of calbindin, Ab42,
and age.
Conclusions/Significance: Using a targeted proteomic screen, we identified novel candidate biomarkers that complement
the best current CSF biomarkers for distinguishing very mildly/mildly demented from cognitively normal individuals.
Additionally, we identified a novel biomarker (calbindin) with significant prognostic potential.
Citation: Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, et al. (2011) Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer’s
Disease Diagnosis and Prognosis. PLoS ONE 6(4): e18850. doi:10.1371/journal.pone.0018850
Editor: Ashley I. Bush, Mental Health Research Institute of Victoria, Australia
Received November 28, 2010; Accepted March 21, 2011; Published April 19, 2011
Copyright:  2011 Craig-Schapiro et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a grant to Washington University from Pfizer. Max Kuhn, Eve H. Pickering, Thomas P. Misko, Kelly R. Bales and Holly Soares
are employed by Pfizer Global Research and Development, Groton, CT, and St. Louis, MO and therefore, Pfizer Global played a role in study design, data collection
and analysis, decision to publish, and preparation of the manuscript. This work was also supported by the National Institutes of Health grants P50 AG05681, P01
AG03991, P01 AG026276, P30 NS057105 and the Charles and Joanne Knight Alzheimer Research Initiative. This publication was made possible by Grant Number
UL1 RR024992 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical
Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. In regard to the funders other
than Pfizer, they had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: Max Kuhn, Eve H. Pickering, Kelly R. Bales are paid employees
of Pfizer. They have no other competing interests relevant to the data in this manuscript. Thomas P. Misko and Holly Soares were paid employees of Pfizer during
the course of this study. They have no other competing interests relevant to the data in this manuscript. David M. Holtzman co-founded the company C2N
Diagnostics and has ownership interests. He serves on the Scientific Advisory Boards of En Vivo and Satori. He has no other competing interests relevant to the
data in this manuscript. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials. Rebecca Craig-Schapiro, Chengjie
Xiong, Jingxia Liu, Richard J. Perrin, and Anne M. Fagan have no competing interests to declare.
* E-mail: holtzman@neuro.wustl.edu
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18850Introduction
With the growing prevalence of Alzheimer’s disease (AD), the
ability to accurately and reliably diagnose AD in its earliest stages
has become a public health priority. The concept of ‘earliest
stages,’ however, warrants revision as it is increasingly clear there
exists a ‘preclinical’ or ‘presymptomatic’ stage during which the
pathological changes associated with AD, amyloid plaques,
neurofibrillary tangles, and neuroinflammation, begin to appear
without concomitant clinical features. This period has been
estimated to be ,10–15 years in duration. Means to identify this
preclinical phase of AD may facilitate medical intervention to
prevent or slow neurodegeneration and the resulting cognitive
impairment. Because clinical examination cannot detect preclin-
ical disease and is less accurate with very mild stages of AD, there
is a pressing need for biomarkers for AD. Furthermore,
biomarkers may have significant utility in clinical trial design,
providing greater diagnostic certainty for enrollment than is
possible by clinical diagnosis alone, and allowing for the selective
enrollment of individuals at greater risk of developing future
cognitive impairment, ultimately resulting in trials of shorter
duration, smaller size, and reduced cost.
The cerebrospinal fluid (CSF) is a logical source of potential AD
biomarkers, as it reflects biochemical changes in the brain. Indeed,
the fluid biomarkers thus far showing the greatest promise for use
in AD diagnosis and prognosis are CSF amyloid-b42 (Ab42), tau,
and phosphorylated forms of tau (p-tau) [1]–[5]. Concentrations of
CSF Ab42 decrease in association with the deposition of Ab42 into
plaques within the brain [6]–[9]. This process occurs years prior to
the clinical onset of AD and may mark the earliest phase of AD
pathology. CSF Ab42 levels remain low throughout the disease
course [6], [10], [11]. In contrast, CSF tau and p-tau levels
progressively increase with the advancing stages of AD, and in
some individuals, begin to rise several years prior to diagnosis [7],
[12], [13]. The ratios of tau or p-tau to Ab42 have also proven
useful for predicting clinical progression in individuals who have
very mild dementia or mild cognitive impairment (MCI), and,
importantly, for predicting future MCI and AD dementia among
those who are cognitively normal [7], [14], [15]. Nevertheless,
even for these analytes, there is substantial overlap between
control and AD groups and a need for better prognostic ability
[16]. Consequently, there remains a need for supplemental
biomarkers to improve diagnosis and prognosis at different disease
stages. Given the multifactorial nature of AD pathophysiology, it is
likely that there will be other CSF biomarkers that will be useful in
this regard. While proteomic screens have identified a number of
other candidate AD biomarkers [17]–[26], few studies have
utilized large, well-characterized cohorts or have looked for
biomarkers in preclinical or very early stage disease.
In this study, a large number of CSF samples (N=333) selected
from well-characterized MCI/very early stage-AD and cognitively
normal control cohorts were chosen for protein profiling using a
commercially available panel that measures a variety of cytokines,
chemokines, metabolic markers, growth factors, and other
markers. Multiplex immunoassay platforms such as the one used
here, Rules Based Medicine Discovery MAP 1.0 panel, allow for
the simultaneous quantitation of many analytes, and by adhering
to clinical laboratory improvement amendments (CLIA) standards,
are amenable for clinical trial work. Using multiple statistical
approaches, we have identified a set of novel biomarkers that may
improve the ability of traditional AD biomarkers, Ab42 and tau, to
distinguish MCI/early-stage AD from cognitive normalcy and to
predict the development of future cognitive impairment (i.e.
detection of preclinical AD at increased risk of progression).
Methods
Ethics Statement
The study protocols were approved by the Human Studies
Committees at all participating institutions, and written and verbal
informed consent was obtained from participants at enrollment.
All aspects of this study were conducted according to the principles
expressed in the Declaration of Helsinki.
Participant Selection
Participants (N=333) were community-dwelling volunteers
enrolled in longitudinal studies of healthy aging and dementia at
the Knight Alzheimer’s Disease Research Center at Washington
University (WU-ADRC). The study protocol was approved by the
Human Studies Committee at Washington University, and written
and verbal informed consent was obtained from participants at
enrollment. At sample collection, participants were $60 years of
age and in good general health, having no other neurological,
psychiatric, or major medical diagnoses that could contribute
importantly to dementia. Clinical diagnosis was evaluated based
on criteria from the National Institute of Neurological and
Communicative Diseases and Stroke-Alzheimer’s Disease and
Related Disorders Association (NINCDS-ADRDA) [27]. Cogni-
tive status was rated with the clinical dementia rating scale (CDR);
a CDR of 0 (N=242) indicated no dementia, CDR 0.5 (N=63)
indicated very mild dementia, and CDR 1 (N=28) indicated mild
dementia [28]. Some of the CDR 0.5 study participants met the
criteria for mild cognitive impairment (MCI) and some were more
mildly impaired and were considered ‘‘pre-MCI’’ [29], [30]. A
subset of participants (N=179) in this cohort had also undergone
positron emission tomography (PET) imaging with Pittsburgh
Compound-B (PIB) for assessment of in vivo amyloid burden [32].
A mean cortical PIB binding potential value was obtained by
averaging prefrontal cortex, precuneus, lateral temporal cortex,
and gyrus rectus regions, as described previously [6], [31].
Apolipoprotein E (APOE) genotype was determined by the WU-
ADRC Genetics Core. Twenty-five to 30 mL of CSF was
collected by lumbar puncture (LP) at 8 AM following overnight
fasting. Samples were inverted to avoid gradient effects, centri-
fuged briefly (2,000g, 5 minutes, 4uC) to remove any cellular
elements, and aliquoted into polypropylene tubes for freezing and
storage at 280uC [7].
Analyte Measurements
CSF Ab42, total tau, and phospho-tau181 levels (henceforth
referred to as ‘traditional’ biomarkers) were analyzed in duplicate
by the WU-ADRC Biomarker Core by quantitative ELISA after a
single freeze-thaw cycle according to the manufacturer’s specifi-
cations (Innotest, Innogenetics, Ghent, Belgium).
CSF samples were also evaluated by Rules Based Medicine, Inc.
(RBM) (Austin, TX) for levels of 190 analytes using the Human
Discovery Multi-Analyte Profile (MAP) 1.0 panel and a Luminex
100 platform. This 190 analyte panel (from here on referred to as
‘RBM analytes’) was assembled by RBM to measure a range of
cytokines, chemokines, growth factors, hormones, metabolic
markers, and other proteins thought to be important in disease;
a complete list of analytes is available at www.rulesbasedmedicine.
com.
At RBM, the samples were thawed at room temperature (RT),
vortexed, spun at 13,000g for 5 minutes for clarification, and 1.0
mL was removed into a master microtiter plate for MAP analysis.
Using automated pipetting, an aliquot of each sample was
introduced into one of the capture microsphere multiplexes of
the Human DiscoveryMAP. The mixtures of sample and capture
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hour. Multiplexed cocktails of biotinylated reporter antibodies for
each multiplex were then added robotically, and after thorough
mixing, were incubated for an additional hour at RT. Multiplexes
were developed using an excess of streptavidin-phycoerythrin
solution which was thoroughly mixed into each multiplex and
incubated for 1 hour at RT. The volume of each multiplexed
reaction was reduced by vacuum filtration and then increased by
dilution into matrix buffer for analysis. Analysis was performed in
a Luminex 100 instrument and the resulting data stream was
interpreted using proprietary data analysis software developed at
RBM. For each multiplex, both calibrators and controls were
included on each microtiter plate. Eight-point calibrators were run
in the first and last column of each plate and 3-level quality
controls were included in duplicate. Testing results were
determined first for the high, medium and low controls for each
multiplex to ensure proper assay performance. Unknown values
for each of the analytes localized in a specific multiplex were
determined using 4 and 5 parameter, weighted and non-weighted
curve fitting algorithms included in the data analysis package.
Statistical Analysis
Statistical analyses were performed in SAS 9.2 (SAS Institute
Inc, Cary, NC) for univariate analyses, ROC/AUC calculations,
and Cox proportional hazards models, and in R version 2.10.1 for
predictive modeling [packages/versions: caret (4.65), earth (2.4-0),
kernlab (0.9–9), klaR (0.6–3), MASS (7.3–7), mda (0.4–1), nnet
(7.3–1), pamr (1.44.0), pls (2.1–0), randomForest (4.5–34), spls
(2.1–0)] [33]. Of the 190 RBM analytes, 65 had .10% of data
missing or below the lower detection limit (LDL), and were
therefore excluded from analysis, yielding 125 ‘measurable’
analytes. Data below the LDL were imputed to LDL/2, and data
more than five standard deviations beyond the mean were
imputed using a nearest neighbor algorithm. Of the 125
measurable analytes, 24 analytes had at least one value below
the LDL, imputed to LDL/2. For those 24 analytes, the
percentage of data imputed ranged from , 1% (3 or fewer
values) to 9.5% (33 values). There were a total of 82 outliers from
48 participants, with outliers in a maximum of 10 analytes for one
participant, and in 2 – 9 analytes for the remaining participants.
The distributions of analytes were tested for normality by Box-Cox
analysis and, when appropriate, log10 transformed to approximate
a normal distribution. Correlations between RBM analytes,
traditional AD biomarkers, and demographic variables were
evaluated using the Spearman rho correlation coefficient
(a=0.05). Analysis of covariance (ANCOVA) using the General
Linear Model (GLM) procedure in SAS was used to determine
analytes that differed in concentration between AD and control
groups while adjusting for the effects of age and gender.
Bonferroni correction was used to adjust for multiple testing
(128 RBM plus traditional analytes). For each analyte showing
promise by univariate analysis, the area under the Receiver
Operating Characteristic (ROC) curve (AUC) was calculated for
discriminating CDR 0 versus CDR.0. The method of Xiong et
al. [34] was implemented to determine the optimum linear
combination of analytes and to calculate the confidence interval
(CI) on the AUC and the sensitivity. A bootstrapping resampling
technique was used to obtain robust estimates of expected future
performance of the three marker panels in predicting CDR 0
versus CDR.0. Averages of performance measures (the 95% CI
of the AUC, sensitivity at 80% specificity, and p-value) were taken
over 100 iterations of the bootstrap.
Cox proportional hazard models assessed the ability of baseline
biomarkers to predict conversion from cognitive normalcy (CDR
0) to very mild or mild dementia (CDR 0.5 and 1). Data from
participants who did not convert during the follow-up were
statistically censored at the date of last assessment. Biomarker
measurements were treated as continuous variables and were
converted to standard Z-scores. Baseline variables were considered
for inclusion in multivariate models if they were associated with
time to conversion in a univariate analysis (p,0.15). Variables
were retained in multivariate proportional hazard models if
p,0.05. AIC (Akaike Information Criterion), a measure of
goodness of fit of an estimated statistical model, was used to
compare different models, with a lower AIC indicating better
model fit.
Several statistical machine learning techniques were utilized to
predict CDR status as a function of baseline characteristics (e.g.
age) and the candidate biomarkers. Rather than focusing on a
specific model, a panel of predictive modeling techniques was
applied to the data. Most of these models contain ‘‘tuning
parameters’’ that cannot be directly estimated from the data; these
values were chosen using resampling techniques. The models used
were:
N Partial Least Squares (PLS) is a latent variable model that
produces linear class boundaries and works well with
correlated predictors [35]. Candidate values of the tuning
parameter, the number of PLS components, ranged from 1 to
20.
N Sparse Partial Least Squares (SPLS) is a variant of PLS that
incorporates feature selection in the model fitting [36]. The
number of PLS components was varied in the same manner as
the basic PLS model and the additional tuning parameter for
regularization was varied from 0.1 to 0.9.
N Random Forests (RF) is a tree-based ensemble method [37].
The number of randomly selected variables at each split was
varied over five values (generally 2 to the number of predictors
in the model).
N Boosted Trees are another tree-based ensemble model [38].
The three tuning parameters are the depth of the tree (even
values from 2 to 10 were evaluated), the number of boosting
iterations (20 iterations to 2000 in 100 iteration increments)
and the learning rate (fixed at 0.1).
N Support Vector Machine (SVM) are a kernel based method
[39]. The radial basis function kernel was used. The kernel
parameter was estimated analytically [40] and the five
candidate values of the cost parameter ranged from 0.1 to
1,000 on the log10 scale.
N Nearest Shrunken Centroids (NCS) is a prototype model that
incorporates feature selection [41]. The tuning parameter, the
shrinkage threshold, was varied over 30 values (between 0.325
and 9.097 for the model using traditional biomarkers, and
between 0.325 and 9.11 for the model using traditional and
RBM markers.)
N Naı ¨ve Bayes (NB) is a simple classifier where each predictor
variable contributes to the final class prediction independently
[42]. The conditional distributions were computed using a
simple Gaussian distribution or using a nonparametric density
estimator.
N K-Nearest Neighbors (KNN) is a simple prototype based
model [42]. Candidate values for the number of neighbors
ranged from 5 to 15.
N Flexible Discriminant Analysis (FDA) is a partitioning based
model that also incorporates feature selection [43]. The
multivariate adaptive spline basis function was used. Ten
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evaluated.
To determine the values for the tuning parameters and to estimate
performance, resampling methods were used. The entire data set
was repeatedly split into training (80%) and test sets (20%). This
process was repeated 200 times. Models were fit on the training
sets and the associated held-out values were used to estimate
performance (sensitivity, specificity, and the area under the ROC
curve). The final estimates of performance were calculated by
averaging the 200 sets of performance values from the resampling
procedure.
Results
Levels of 37 markers are altered in MCI/very mild and
mild AD CSF
To identify new candidate biomarkers for AD, multiplexed
Luminex-based immunoassays were used to evaluate the levels of
190 analytes in the CSF of 242 cognitively normal participants
(CDR 0), 63 participants with very mild dementia (CDR 0.5), and
28 participants with mild dementia (CDR 1) (participant
characteristics at baseline assessment in Table 1). Since the
number of CDR 1 participants was relatively smaller, and all CDR
0.5 and CDR 1 participants were clinically diagnosed as having
AD, the CDR 0.5 and CDR 1 groups were combined in the
statistical analyses. There were no statistically significant differ-
ences in age, gender, MCBP for PIB-PET, or APOE genotype
between the CDR 0.5 and CDR 1 groups. Of the 125 RBM
analytes that were statistically assessed (Table S1), the mean
concentrations of 37 CSF analytes were found to differ between
cognitively normal (CDR 0) and very mildly/mildly demented
(CDR 0.5 and 1) participants by analysis of covariance
(ANCOVA) adjusting for age and gender (p,0.05) (Table 2 and
Table S2). Twelve of these 37 analytes remained significant after
Bonferroni correction for multiple testing (n=128, adjusted alpha
=0.0004). Additionally, participants with very mild/mild demen-
tia exhibited the typical AD CSF biomarker profile characterized
by significantly lower mean levels of CSF Ab42 and higher mean
levels of CSF tau and CSF p-tau181, as well as displaying higher
mean cortical amyloid burden (MCBP assessed by PIB-PET
imaging) as has been seen previously (Tables 1 and 2) [6], [31],
[32].
Correlation of RBM analytes with demographic features
and other biomarker values
Because the CDR 0, 0.5, and 1 groups showed somewhat
different distributions with regard to age at lumbar puncture and
gender, levels of the 37 RBM analytes were evaluated for
correlation with these variables. Many analytes were significantly
associated with age or gender (Table 3). Additionally, seeking
insight into the potential roles of the analytes in AD pathology, we
evaluated their association with CSF Ab42, tau, and p-tau181, and
cortical amyloid burden measured by PIB-PET imaging. Many of
the analytes correlated with CSF tau and CSF p-tau181 (31 and 30
analytes, respectively), while fewer correlated with CSF Ab42 or
cortical amyloid burden (8 and 5 analytes, respectively) (Table 3).
Diagnostic Utility of Candidate Biomarkers
To assess the potential of the analytes for identifying very mild/
mild dementia (combined CDR 0.5 and CDR 1), ROC curves and
AUCs were calculated for each of the 37 RBM analytes and for
traditional AD biomarkers Ab42, tau, p-tau181 and the ratios tau/
Ab42 and p-tau181/Ab42 (Table 4 and Figure 1). Although none
of the RBM analytes alone out-performed the traditional
biomarkers, combining traditional biomarkers with RBM analytes
improved upon the AUC of the traditional biomarkers in many
cases; e.g., Ab42: AUC= .7552, combinations ranging from
.7553–.8201; tau/Ab42: AUC= .8443, combinations ranging
from .8444–.8819; p-tau181/Ab42: AUC= .8065, combinations
ranging from .8065–.8468 (Table 4 and Figure 1). For these ‘2-
marker panels’ of traditional biomarker plus RBM analyte,
combinations with tau/Ab42 consistently yielded the highest
AUCs. To investigate whether combinations of three markers
could yield a small panel with improved diagnostic accuracy, we
utilized a targeted approach in which the four 2-marker panels
with the highest AUCs (tau/Ab42 + cystatin C, tau/Ab42 +
VEGF, tau/Ab42 + KIM-1, tau/Ab42 + PP) were combined with
the 10 RBM analytes with the highest individual AUCs (indicated
in Table 4). Because an independent validation cohort was not
available for analysis, bootstrapping resampling with 100 iterations
was performed to obtain relatively unbiased estimates of expected
future performance of the ‘3-marker panels’ in predicting CDR 0
versus CDR.0 (Table 5). A number of the 3-marker panels
demonstrated significantly improved AUCs compared to the
corresponding 2-marker panels, with the best achieving AUCs of
,.90 and sensitivities of ,84% at 80% specificity (Table 5).
Because AD is a complex, multifactorial disease and likely
involves alterations in multiple biological pathways, it is possible
that a larger panel of biomarkers encompassing various features of
AD pathophysiology may be optimal for disease diagnosis. Thus,
we utilized statistical machine learning algorithms, which are more
amenable to potentially large numbers of analyte combinations
and can identify highly complex nonlinear relationships, to
discover whether groups of markers are capable of distinguishing
very mildly/mildly demented (CDR 0.5 and 1 combined) from
cognitively normal participants (CDR 0). A multi-pronged
analytical approach including RF, PLS, SPLS, Boosted Tree,
FDA, NB, NSC, LR, KNN, and SVM was used, as each approach
has its own strengths and weaknesses. Models were fit with two sets
of predictors: 1) traditional biomarkers, and 2) traditional
biomarkers plus RBM analytes; additionally, age, gender, and
ApoE genotype were included in all models. Model performance
measures were based on cross-validation, in which the test set
results were averaged from 200 splits of the data between training
Table 1. Demographic, clinical, and genotypic characteristics
of the 333 study participants.
Characteristic CDR 0 CDR 0.5 CDR 1
N 242 63 28
Gender (% Female) 65% 52% 50%
APOE genotype, % e4+ 32% 54% 57%
Mean MMSE score (SD) 28.9 (1.3) 26.3 (2.8) 22.5 (4.0)
Mean age at LP (SD), yrs 71.6 (7.4) 74.6 (7.3) 76.8 (6.2)
Mean CSF Ab42 (SD), pg/mL 607 (234) 436 (233) 355 (119)
Mean CSF tau (SD), pg/mL 315 (169) 547 (278) 557 (266)
Mean CSF p-tau181 (SD), pg/mL 56 (25) 85 (45) 78 (38)
Mean PIB MCBP (SD) 0.12 (0.24) 0.54 (0.34) 0.50 (0.50)
Abbreviations: CDR, Clinical Dementia Rating; APOE, apolipoprotein E; MMSE,
Mini-Mental State Examination; LP, lumbar puncture; SD, standard deviation;
CSF, cerebrospinal fluid; Ab-42, amyloid-beta peptide 1-42; p-tau181, tau
phosphorylated at threonine 181; PIB MCBP, Pittsburgh Compound B mean
cortical PIB binding potential. MCBP data available for 179 study participants.
doi:10.1371/journal.pone.0018850.t001
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or traditional biomarkers with RBM analytes, no model clearly
out-performed the others; however, the RBM analytes appeared to
contribute additional specificity to the biomarker panels (tradi-
tional: sensitivity 80.6–91.4%, specificity 42.4–56.6%; traditional+
RBM: sensitivity 79.1–93.2%, specificity 59.6–77.6%). This
Table 2. Analytes that differ in levels between cognitively normal (CDR 0) and very mildly/mildly demented (CDR 0.5 and 1)
participants.
Marker
Adjusted
mean CDR 0
Adjusted
mean CDR.0p
Raw mean
CDR 0
Raw mean
CDR.0
Ab42 (pg/mL)* 607.45 418.85 ,0.0001 606.90 411.18
Tau (pg/mL)* 315.59 533.60 ,0.0001 314.80 549.96
p-tau181 (pg/mL)* 56.30 81.01 ,0.0001 56.32 82.98
Growth-Regulated alpha protein (GRO-a) (pg/mL)* 18.27 22.09 ,0.0001 18.30 22.44
Log Matrix Metalloproteinase-10 (MMP-10) (pg/mL)* 24.84 31.41 ,0.0001 24.11 32.61
Log N-terminal pro-brain natriuretic peptide (NT-proBNP) (pg/mL)* 87.00 107.75 ,0.0001 87.70 111.12
Log Plasminogen Activator Inhibitor 1 (PAI-1) (ng/mL)* 1.05 1.28 ,0.0001 1.01 1.34
TNF-Related Apoptosis-Inducing Ligand Receptor 3 (TRAIL-R3) (ng/mL)* 0.55 0.63 ,0.0001 0.55 0.65
Vascular Endothelial Growth Factor (VEGF) (pg/mL)* 441.57 378.30 ,0.0001 437.83 386.01
Log Pancreatic Polypeptide (PP) (pg/mL)* 0.94 1.30 0.0001 0.88 1.41
Log FAS (ng/mL)* 0.57 0.65 0.0002 0.56 0.67
Log Macrophage Migration Inhibitory Factor (MIF) (ng/mL)* 0.15 0.17 0.0004 0.15 0.18
Interleukin-7 (IL-7) (pg/mL) 12.63 9.47 0.0006 12.23 9.68
Log Cystatin C (ng/mL) 5613.84 4750.89 0.0011 5551.50 4835.30
Thrombopoietin (ng/mL) 0.43 0.37 0.0016 0.42 0.37
Sortilin (ng/mL) 6.32 6.92 0.0019 6.33 6.96
Monocyte Chemotactic Protein 2 (MCP-2) (pg/mL) 4.03 4.61 0.0020 3.97 4.67
Log Fibrinogen (ug/mL) 0.63 0.78 0.0024 0.59 0.81
Log Creatine Kinase-MB (CKMB) (pg/mL) 26.55 20.97 0.0030 26.62 20.87
Cortisol (ng/mL) 11.21 12.65 0.0034 11.17 12.89
Thymus-Expressed Chemokine (TECK) (ng/mL) 6.38 6.85 0.0039 6.30 6.96
Eotaxin-3 (pg/mL) 56.78 62.09 0.0057 55.33 63.68
Interleukin-17E (IL-17E) (pg/mL) 8.63 7.75 0.0058 8.60 7.79
Kidney Injury Molecule-1 (KIM-1) (pg/mL) 78.97 83.46 0.0074 79.05 83.08
Log Heparin-binding epidermal growth factor-like growth factor (HB-EGF) (pg/mL) 24.98 28.77 0.0077 25.05 28.70
Log Osteopontin (ng/mL) 173.23 197.68 0.0078 174.15 202.31
Log a-1-Antitrypsin (ug/mL) 4.87 5.37 0.0102 4.73 5.49
Fatty Acid Synthase Ligand (FASL) (pg/mL) 4.85 5.40 0.0109 4.78 5.49
Log Insulin-like Growth Factor-Binding Protein 2 (IGFBP-2) (ng/mL) 199.58 212.16 0.0111 195.93 217.47
Log Interleukin-10 (IL-10) (pg/mL) 1.14 1.29 0.0131 1.12 1.29
Log Tumor necrosis factor-a receptor 2 (TNF RII) (ng/mL) 0.53 0.59 0.0141 0.52 0.62
Log Resistin (pg/mL) 26.28 30.76 0.0146 25.20 32.14
Log Fatty Acid Binding Protein (FABP) (ng/mL) 3.03 3.62 0.0209 2.93 3.81
Log Apolipoprotein D (ApoD) (ug/mL) 4.18 4.57 0.0318 4.02 4.65
Log Hepatocyte Growth Factor (HGF) (ng/mL) 1.18 1.28 0.0349 1.18 1.30
Log Insulin (uIU/mL) 0.22 0.19 0.0359 0.21 0.19
Log Hemofiltrate cysteine-cysteine chemokine (HCC-4) (pg/mL) 30.25 33.13 0.0418 28.98 33.87
Log Interferon gamma Induced Protein 10 (IP-10) (pg/mL) 299.63 341.86 0.0432 295.14 354.74
Log Gamma-Interferon-Induced Monokine (MIG) (pg/mL) 423.80 493.91 0.0452 400.16 572.75
Thrombomodulin (ng/mL) 0.17 0.18 0.0475 0.17 0.19
Analysis of covariance (ANCOVA) using the General Linear Model (GLM) procedure in SAS was used to determine analytes that differed in concentration (p,0.05)
between CDR 0 and CDR.0 groups while adjusting for the effects of age and gender ("adjusted means").
*indicates analytes that were significant after Bonferroni correction based on the number of markers analyzed (128 markers, cutoff of 0.0004 for familywise p,0.05). For
markers that were log transformed to approximate a normal distribution, the resulting Least Squares mean (or estimated marginal mean) was back-transformed to
obtain the adjusted mean shown. Also provided are the raw mean concentrations for the CDR 0 and CDR.0 groups.
doi:10.1371/journal.pone.0018850.t002
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statistic that captures the performance of a diagnostic test and is a
function of sensitivity and specificity, which was higher on average
for the models fitted with traditional plus RBM analytes
(traditional: 0.230–0.438; traditional+RBM: 0.401–0.621). Addi-
tionally, models fitted with traditional plus RBM analytes yielded
mostly higher AUCs (traditional: 0.680–0.827; traditional+RBM:
0.754–0.868). For the four models with a built-in importance
statistic (i.e., Boosted Tree, NSC, RF, and PLS) there was
considerable overlap in the top 15 predictors for each model
(Figure 2, Table 7). Importantly, nearly all of the markers found to
best discriminate CDR 0 from CDR.0 participants in the more
targeted ROC analyses (Table 5) were also identified as the top
predictors in the machine learning models (Figure 2, Table 7),
reconfirming the potential of these analytes as biomarkers for AD.
Prognostic Utility of Candidate Biomarkers
Identifying individuals with AD neuropathology while they are
still in the preclinical phase will be critically important, as disease-
modifying therapies currently in development are likely to be most
Table 3. Correlations of RBM analytes with age, gender, and other biomarker values.
Analyte Gender Age Ab42 Tau p-tau181 tau/Ab42 Cortical PIB
a1A ,0.001 0.255 (,0.0001) 0.031 (0.574) 0.117 (0.033) 0.105 (0.055) 0.048 (0.386) -0.048 (0.525)
ApoD ,0.001 0.218 (,0.0001) 0.059 (0.280) 0.222 (,0.0001) 0.216 (,0.0001) 0.113 (0.039) -0.103 (0.169)
Calbindin 0.001 0.196 (,0.001) 0.094 (0.088) 0.476 (,0.0001) 0.500 (,0.0001) 0.294 (,0.0001) 0.122 (0.104)
CKMB 0.524 -0.069 (0.211) 0.008 (0.877) -0.200 (,0.001) -0.186 (0.001) -0.148 (0.007) 0.032 (0.673)
Cortisol 0.282 0.252 (,0.0001) -0.051 (0.357) 0.187 (0.001) 0.189 (0.001) 0.159 (0.004) 0.012 (0.875)
Cystatin C 0.461 0.093 (0.089) 0.281 (,0.0001) 0.536 (,0.0001) 0.597 (,0.0001) 0.236 (,0.0001) -0.041 (0.587)
Eotaxin-3 ,0.001 0.317 (,0.0001) 0.058 (0.289) 0.367 (,0.0001) 0.342 (,0.0001) 0.217 (,0.0001) 0.003 (0.971)
FABP 0.031 0.296 (,0.0001) 0.012 (0.833) 0.727 (,0.0001) 0.725 (,0.0001) 0.505 (,0.0001) 0.159 (0.034)
FAS ,0.001 0.297 (,0.0001) 0.083 (0.132) 0.491 (,0.0001) 0.470 (,0.0001) 0.288 (,0.0001) -0.074 (0.326)
FASL 0.165 0.192 (,0.001) -0.060 (0.274) 0.189 (0.001) 0.200 (,0.001) 0.129 (0.018) -0.020 (0.795)
Fibrinogen ,0.001 0.284 (,0.0001) -0.044 (0.422) 0.192 (,0.001) 0.178 (0.001) 0.145 (0.008) 0.034 (0.652)
GRO-a 0.178 0.279 (,0.0001) -0.105 (0.056) 0.317 (,0.0001) 0.329 (,0.0001) 0.259 (,0.0001) 0.144 (0.054)
HB-EGF 0.975 0.017 (0.751) 0.079 (0.151) 0.348 (,0.0001) 0.359 (,0.0001) 0.202 (,0.001) -0.024 (0.751)
HCC-4 ,0.001 0.240 (,0.0001) 0.007 (0.895) 0.094 (0.088) 0.037 (0.504) 0.047 (0.388) -0.095 (0.204)
HGF 0.918 0.222 (,0.0001) 0.088 (0.110) 0.619 (,0.0001) 0.639 (,0.0001) 0.386 (,0.0001) 0.004 (0.957)
IGFBP-2 ,0.001 0.394 (,0.0001) 0.062 (0.262) 0.462 (,0.0001) 0.441 (,0.0001) 0.278 (,0.0001) 0.031 (0.685)
IL-17E 0.386 0.032 (0.563) 0.017 (0.760) 0.007 (0.899) 0.049 (0.371) 0.019 (0.725) -0.101 (0.180)
IL-7 0.007 0-.002 (0.976) 0.147 (0.007) -0.003 (0.961) 0.032 (0.557) -0.091 (0.096) -0.227 (0.002)
IL-10 ,0.001 0.055 (0.313) -0.026 (0.637) 0.070 (0.205) 0.075 (0.170) 0.053 (0.337) -0.071 (0.342)
IP-10 0.327 0.236 (,0.0001) 0.023 (0.682) 0.249 (,0.0001) 0.282 (,0.0001) 0.147 (0.007) -0.071 (0.344)
Insulin ,0.001 0.094 (0.088) 0.245 (,0.0001) 0.213 (,0.0001) 0.214 (,0.0001) 0.005 (0.921) -0.190 (0.011)
KIM-1 0.636 0-.032 (0.561) -0.057 (0.301) -0.239 (,0.0001) -0.331 (,0.0001) -0.154 (0.005) -0.060 (0.427)
MCP-2 0.013 0.146 (0.007) -0.106 (0.053) 0.045 (0.408) 0.059 (0.282) 0.071 (0.199) -0.011 (0.880)
MIF 0.239 0.330 (,0.0001) -0.007 (0.901) 0.579 (,0.0001) 0.597 (,0.0001) 0.412 (,0.0001) 0.084 (0.264)
MIG 0.528 0.603 (,0.0001) -0.017 (0.762) 0.282 (,0.0001) 0.289 (,0.0001) 0.207 (,0.001) -0.053 (0.484)
MMP-10 0.002 0.325 (,0.0001) -0.116 (0.034) 0.458 (,0.0001) 0.415 (,0.0001) 0.390 (,0.0001) 0.086 (0.252)
NT-proBNP 0.030 0.273 (,0.0001) 0.053 (0.338) 0.331 (,0.0001) 0.323 (,0.0001) 0.188 (0.001) -0.007 (0.923)
Osteopontin 0.137 0.192 (,0.001) 0.030 (0.590) 0.680 (,0.0001) 0.701 (,0.0001) 0.466 (,0.0001) 0.162 (0.030)
PP ,.001 0.374 (,0.0001) -0.072 (0.189) 0.226 (,0.0001) 0.179 (0.001) 0.192 (,0.001) 0.041 (0.586)
PAI-1 ,.001 0.429 (,0.0001) -0.064 (0.244) 0.334 (,0.0001) 0.327 (,0.0001) 0.266 (,0.0001) -0.003 (0.973)
Resistin ,.001 0.355 (,0.0001) 0.072 (0.189) 0.255 (,0.0001) 0.198 (,0.0001) 0.120 (0.029) -0.075 (0.320)
Sortilin 0.881 0.135 (0.014) 0.139 (0.011) 0.515 (,0.0001) 0.527 (,0.0001) 0.273 (,0.0001) -0.003 (0.972)
TNF RII 0.205 0.426 (,0.0001) 0.059 (0.282) 0.678 (,0.0001) 0.702 (,0.0001) 0.442 (,0.0001) 0.002 (0.975)
TRAIL-R3 0.112 0.413 (,0.0001) -0.011 (0.837) 0.509 (,0.0001) 0.476 (,0.0001) 0.356 (,0.0001) 0.008 (0.914)
Thrombomodulin ,.001 0.193 (,0.001) 0.109 (0.048) 0.215 (,0.0001) 0.205 (,0.001) 0.076 (0.168) -0.063 (0.406)
Thrombopoietin 0.015 0.034 (0.531) 0.194 (,0.001) -0.016 (0.768) 0.017 (0.758) -0.130 (0.017) -0.237 (0.001)
TECK 0.015 0.270 (,0.0001) 0.047 (0.389) 0.322 (,0.0001) 0.312 (,0.0001) 0.193 (,0.001) 0.001 (0.992)
VEGF 0.651 0.101 (0.065) 0.357 (,0.0001) 0.470 (,0.0001) 0.543 (,0.0001) 0.154 (0.005) -0.059 (0.429)
Correlations were evaluated using the Spearman rho correlation coefficient (a=0.05); shown are the r and (p value). Gender differences were evaluated by Mann-
Whitney test.
doi:10.1371/journal.pone.0018850.t003
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AUC of Traditional Biomarkers
log Ab42 0.7552
log tau 0.7830
log p-tau181 0.7149
log tau/Ab42 0.8443
log p-tau181/Ab42 0.8065
AUC of RBM Biomarkers: alone and in combination with traditional biomarkers
Marker Marker+log tau/Ab42 Marker+log p-tau181/Ab42
log a1A 0.6296 0.8578 0.8234
log ApoD 0.6136 0.8489 0.8138
log CKMB 0.6106 0.8475 0.8118
Cortisol 0.6183 0.8510 0.8155
log Cystatin C 0.5965 0.8819 1 0.8468
Eotaxin-3 0.6448 1 0.8516 0.8202
log FABP 0.6163 0.8499 0.8080
log FAS 0.6689 1 0.8518 0.8209
FASL 0.6134 0.8479 0.8116
log Fibrinogen 0.6503 1 0.8564 0.8232
GRO-a 0.7024 1 0.8609 0.8305
log HB-EGF 0.5929 0.8445 0.8081
log HCC-4 0.6172 0.8596 0.8281
log HGF 0.5972 0.8458 0.8069
log IGF-BP2 0.6378 0.8462 0.8116
IL-7 0.6029 0.8508 0.8162
log IL-10 0.6075 0.8575 0.8215
IL-17E 0.5969 0.8487 0.8145
log Insulin 0.5406 0.8453 0.8077
log IP-10 0.5970 0.8460 0.8093
KIM-1 0.5894 0.8668 1 0.8343
MCP-2 0.6264 0.8554 0.8200
log MIF 0.6651 1 0.8455 0.8117
log MIG 0.6376 0.8544 0.8207
log MMP-10 0.6929 1 0.8518 0.8232
log NT-proBNP 0.6753 1 0.8562 0.8248
log Osteopontin 0.6050 0.8508 0.8100
log PP 0.6789 1 0.8644 1 0.8356
log PAI-1 0.6814 1 0.8587 0.8273
log Resistin 0.6218 0.8522 0.8211
Sortilin 0.6177 0.8444 0.8076
log TNF RII 0.6319 0.8447 0.8065
TRAIL-R3 0.6851 1 0.8523 0.8212
Thrombomodulin 0.6004 0.8503 0.8150
Thrombopoietin 0.5898 0.8465 0.8111
TECK 0.6371 0.8525 0.8190
VEGF 0.6146 0.8766 1 0.8441
To assess the ability of the markers to distinguish CDR.0 from CDR 0, ROC analyses were performed for each of the traditional biomarkers (Ab42, tau, p-tau181 and the
ratios tau/Ab42 and p-tau181/Ab42) and for the 37 RBM analytes with p,0.05 in the univariate analyses. Each traditional biomarker was then combined with each RBM
analyte to identify ‘2-marker panels’ with improved AUCs. Among the traditional biomarkers, the ratios tau/Ab42 and p-tau181/Ab42 demonstrated the highest AUCs;
additionally, combining these ratios with the RBM analytes consistently yielded 2-marker panels with AUCs higher than combinations of the individual traditional
biomarkers (Ab42, tau, p-tau181) with the RBM analytes. Thus, only the most promising 2-marker panels (those with tau/Ab42 and p-tau181/Ab42) are shown here. To
determine whether combinations of three markers could yield a small panel with improved diagnostic accuracy, the four 2-marker panels with the highest AUCs were
combined with the 10 RBM analytes with the highest individual AUCs (indicated by 1, results in Table 5).
doi:10.1371/journal.pone.0018850.t004
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neuronal loss has occurred. Thus, we used univariate and
multivariate Cox proportional hazards models to evaluate the
ability of the analytes to predict risk of developing cognitive
impairment (conversion from CDR 0 to CDR.0). Of the 215
CDR 0 subjects with at least one follow-up annual clinical
assessment, 29 received a CDR.0 at follow-up, and thus were
classified as ‘‘converters.’’ Analyte measurements were converted
to standard Z-scores to allow for comparison of hazard ratios
between the different analytes. Variables with p,0.15 in the
univariate Cox analyses were considered for inclusion in the
multivariate model; variables were retained in the final model if
p,0.05. By univariate Cox analysis, calbindin (p=0.0163),
cortisol (p=0.0688), HGF (p=0.1364), MCP-2 (p=0.0412),
MIG (p=0.0208), MIF (p=0.0950), S100B (p=0.1275), TNF
RII (p=0.0645), TRAIL-R3 (p=0.0833), Ab42 (p=,0.0001),
tau (p=0.0071), and p-tau181 (p=0.0087) were selected for
further investigation by multivariate analysis. The final multivar-
iate model consisted of calbindin (HR=1.750, p=0.0063), 1/
Ab42 (HR=2.454, p,0.0001), and age at LP (HR=1.096,
p=0.0002), with an overall HR of 4.704 (Table 8). Although
calbindin and tau both had p,0.05 in the univariate analysis, the
significant correlation between the two (r=0.476, p,0.0001)
prohibited inclusion of both variables in the multivariate model.
Therefore, a second multivariate model consisted of tau
(HR=1.467, p=0.0262), 1/Ab42 (HR=2.247, p,0.0001), and
age at LP (HR=1.098, p=0.0003), with an overall HR of 3.619
(Table 8). However, the higher HR of calbindin than of tau, and
the higher overall HR and lower AIC of the first model support it
as the better model.
Figure 1. ROC analyses, graphical representation. ROC analyses assessed the ability of the traditional biomarkers (blue) and of the 37 RBM
analytes with p,0.05 in the univariate analyses (red) to discriminate CDR.0 from CDR 0 individuals. Combining the best-performing of the
traditional biomarkers, the tau/Ab42 ratio, with RBM analytes improved upon the AUC of tau/Ab42 in many cases (green).
doi:10.1371/journal.pone.0018850.g001
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Biomarkers that can detect AD in its early stages and,
importantly, predict future dementia will be invaluable for efficient
clinical trial design and eventually patient care. This study
identifies novel biomarkers that improve upon the ability of the
best identified biomarkers to date to discriminate very mildly
demented from cognitively normal participants, and identifies a
novel biomarker with significant prognostic potential.
Using Luminex technology and a targeted multiplex panel, we
identified 37 analytes (12 with Bonferroni correction) that are
increased or decreased in the CSF of participants with early AD
Table 5. ROC analyses of 3-marker panels.
Marker Panels AUC Stdev 95% CI
Sensitivity
(at 80%
specificity) Stdev 95% CI p-value Stdev 95% CI
log tau/Ab42 + log Cystatin C + TRAIL-R3 0.9014 0.0232 0.8969–0.9060 0.8367 0.0445 0.8280–0.8455 0.0299 0.0222 0.0255–0.0342
log tau/Ab42 + log Cystatin C + log PAI-1 0.9063 0.0221 0.9020–0.9106 0.8470 0.0438 0.8384–0.8556 0.0283 0.0344 0.0215–0.0351
log tau/Ab42 + log Cystatin C + log PP 0.9066 0.0203 0.9026–0.9106 0.8471 0.0400 0.8393–0.8550 0.0245 0.0319 0.0183–0.0307
log tau/Ab42 + log Cystatin C + NT-proBNP 0.9041 0.0228 0.8996–0.9086 0.8422 0.0445 0.8335–0.8509 0.0287 0.0330 0.0223–0.0352
log tau/Ab42 + log Cystatin C + log MMP-10 0.8987 0.0230 0.8942–0.9032 0.8317 0.0447 0.8230-0.8405 0.0647 0.0582 0.0533–0.0761
log tau/Ab42 + log Cystatin C + log MIF 0.8964 0.0249 0.8915-0.9013 0.8272 0.0487 0.8177–0.8368 0.0699 0.0569 0.0588–0.0811
log tau/Ab42 + log Cystatin C + GRO-a 0.9071 0.0218 0.9028–0.9113 0.8475 0.0412 0.8395–0.8556 0.0347 0.0410 0.0266–0.0427
log tau/Ab42 + log Cystatin C + log Fibrinogen 0.9033 0.0219 0.8990–0.9075 0.8403 0.0429 0.8319–0.8487 0.0357 0.0502 0.0259–0.0455
log tau/Ab42 + log Cystatin C + log FAS 0.9052 0.0220 0.9009–0.9095 0.8440 0.0425 0.8356–0.8523 0.0248 0.0248 0.0200–0.0297
log tau/Ab42 + log Cystatin C + Eotaxin-3 0.9051 0.0219 0.9008–0.9094 0.8441 0.0427 0.8357–0.8524 0.0273 0.0350 0.0205–0.0342
log tau/Ab42 + VEGF + TRAIL-R3 0.9004 0.0226 0.8960–0.9049 0.8347 0.0437 0.8262–0.8433 0.0208 0.0158 0.0177–0.0239
log tau/Ab42 + VEGF + log PAI-1 0.9005 0.0225 0.8961–0.9049 0.8355 0.0445 0.8267–0.8442 0.0272 0.0320 0.0210–0.0335
log tau/Ab42 + VEGF + log PP 0.9039 0.0215 0.8997–0.9081 0.8423 0.0422 0.8340–0.8506 0.0167 0.0250 0.0118–0.0216
log tau/Ab42 + VEGF + NT-proBNP 0.9028 0.0224 0.8984–0.9072 0.8396 0.0439 0.8310–0.8482 0.0165 0.0207 0.0124–0.0205
log tau/Ab42 + VEGF + log MMP-10 0.8947 0.0242 0.8900–0.8995 0.8241 0.0471 0.8149–0.8333 0.0534 0.0519 0.0432–0.0636
log tau/Ab42 + VEGF + log MIF 0.8908 0.0261 0.8857–0.8959 0.8164 0.0506 0.8065–0.8264 0.0703 0.0570 0.0591–0.0815
log tau/Ab42 + VEGF + GRO-a 0.9003 0.0238 0.8956–0.9049 0.8348 0.0452 0.8259–0.8436 0.0365 0.0371 0.0292–0.0437
log tau/Ab42 + VEGF + log Fibrinogen 0.8988 0.0231 0.8943–0.9033 0.8317 0.0449 0.8229–0.8405 0.0327 0.0457 0.0237–0.0416
log tau/Ab42 + VEGF + log FAS 0.9012 0.0232 0.8967–0.9058 0.8363 0.0445 0.8276–0.8451 0.0232 0.0248 0.0183–0.0281
log tau/Ab42 + VEGF + Eotaxin-3 0.8991 0.0227 0.8947–0.9036 0.8325 0.0441 0.8239–0.8411 0.0293 0.0354 0.0224–0.0363
log tau/Ab42 + KIM-1 + TRAIL-R3 0.8810 0.0256 0.8760–0.8860 0.7979 0.0486 0.7884–0.8075 0.1082 0.0747 0.0936–0.1229
log tau/Ab42 + KIM-1 + log PAI-1 0.8866 0.0246 0.8818–0.8915 0.8087 0.0476 0.7993–0.8180 0.0614 0.0607 0.0495-0.0733
log tau/Ab42 + KIM-1 + log PP 0.8905 0.0239 0.8858–0.8952 0.8162 0.0467 0.8070–0.8253 0.0357 0.0452 0.0269–0.0445
log tau/Ab42 + KIM-1 + NT-proBNP 0.8821 0.0260 0.8770–0.8872 0.8001 0.0500 0.7903–0.8099 0.0926 0.0788 0.0772–0.1081
log tau/Ab42 + KIM-1 + log MMP-10 0.8787 0.0270 0.8734–0.8840 0.7940 0.0511 0.7840–0.8040 0.1497 0.1015 0.1298–0.1696
log tau/Ab42 + KIM-1 + log MIF 0.8775 0.0276 0.8721–0.8829 0.7918 0.0518 0.7816–0.8019 0.1478 0.0941 0.1294–0.1663
log tau/Ab42 + KIM-1 + GRO-a 0.8897 0.0242 0.8850–0.8945 0.8153 0.0448 0.8065–0.8241 0.0513 0.0498 0.0416–0.0611
log tau/Ab42 + KIM-1 + log Fibrinogen 0.8821 0.0267 0.8769–0.8874 0.8003 0.0507 0.7903–0.8102 0.0927 0.0809 0.0768–0.1085
log tau/Ab42 + KIM-1 + log FAS 0.8806 0.0248 0.8757–0.8855 0.7973 0.0472 0.7881–0.8066 0.1157 0.0852 0.0990–0.1324
log tau/Ab42 + KIM-1 + Eotaxin-3 0.8805 0.0264 0.8753–0.8857 0.7973 0.0498 0.7875-0.8071 0.1152 0.0943 0.0967–0.1337
log tau/Ab42 + log PP + TRAIL-R3 0.8717 0.0249 0.8668–0.8766 0.7790 0.0488 0.7695–0.7886 0.2225 0.1023 0.2024–0.2425
log tau/Ab42 + log PP + log PAI-1 0.8715 0.0250 0.8666–0.8764 0.7782 0.0498 0.7685–0.7880 0.2034 0.1052 0.1828–0.2240
log tau/Ab42 + log PP + NT-proBNP 0.8723 0.0254 0.8674–0.8773 0.7806 0.0491 0.7710–0.7902 0.1705 0.1051 0.1499–0.1912
log tau/Ab42 + log PP + log MMP-10 0.8702 0.0256 0.8652–0.8753 0.7761 0.0507 0.7662–0.7860 0.2394 0.1204 0.2158–0.2630
log tau/Ab42 + log PP + log MIF 0.8685 0.0251 0.8635–0.8734 0.7723 0.0496 0.7625–0.7820 0.2909 0.1014 0.2711–0.3108
log tau/Ab42 + log PP + GRO-a 0.8755 0.0250 0.8706–0.8804 0.7875 0.0472 0.7783–0.7968 0.1329 0.0908 0.1151–0.1507
log tau/Ab42 + log PP + log Fibrinogen 0.8720 0.0255 0.8670–0.8769 0.7795 0.0498 0.7698–0.7893 0.1878 0.1160 0.1651–0.2106
log tau/Ab42 + log PP + log FAS 0.8701 0.0244 0.8653–0.8749 0.7752 0.0487 0.7657–0.7847 0.2335 0.1091 0.2121–0.2548
log tau/Ab42 + log PP + Eotaxin-3 0.8722 0.0245 0.8674–0.8770 0.7795 0.0487 0.7699–0.7890 0.1813 0.1087 0.1599–0.2026
AUC= area under the curve; Stdev= standard deviation; CI= confidence interval.
Receiver operating characteristic (ROC) analyses assessed the ability of three marker panels to discriminate CDR 0 from CDR.0 participants. Averages of performance
measures were taken over 100 iterations of the bootstrap. ‘‘p-value’’ assesses the difference between the three marker panel and the corresponding two marker panel
(e.g. log tau/Ab42 + log Cystatin C + TRAIL-R3 vs. log tau/Ab42 + log Cystatin C).
doi:10.1371/journal.pone.0018850.t005
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small combinations of a subset of these markers (cystatin C,
VEGF, TRAIL-R3, PAI-1, PP, NT-proBNP, MMP-10, MIF,
GRO-a, fibrinogen, FAS, and eotaxin-3) can enhance the ability
of the best-performing of the traditional biomarkers, the tau/Ab42
ratio, to discriminate CDR 0.5 and 1 from CDR 0 participants.
Figure 2. Venn diagram of the top 15 predictors for machine learning algorithms with a built-in importance measure. For the four
models with a built-in importance statistic (i.e., Boosted Tree, Nearest Shrunken Centroids, Random Forests, and Partial Least Squares), there is
considerable overlap in the top 15 predictors for each model. Additionally, nearly all of the markers found to best discriminate CDR 0 from CDR.0
participants in the more targeted ROC analyses (Table 5), as shown here (‘Targeted’), were also identified as the top predictors in the machine
learning models.
doi:10.1371/journal.pone.0018850.g002
Table 6. Performance measures of machine learning algorithms in discriminating cognitively normal (CDR 0) from very mildly/
mildly demented (CDR 0.5 and 1) participants.
Traditional Biomarkers Traditional + RBM Biomarkers
Model Sensitivity Specificity Youden Index AUC Sensitivity Specificity Youden Index AUC
Boosted Tree 0.843 0.525 0.368 0.782 0.845 0.776 0.621 0.868
Flexible Discriminant Analysis 0.882 0.546 0.428 0.827 0.827 0.672 0.499 0.808
K-Nearest Neighbors 0.866 0.552 0.418 0.813 0.886 0.627 0.513 0.814
Logistic Regression 0.902 0.490 0.392 0.819 0.791 0.667 0.458 0.757
Naı ¨ve Bayes 0.898 0.492 0.390 0.799 0.802 0.599 0.401 0.754
Partial Least Squares 0.914 0.457 0.371 0.822 0.858 0.693 0.551 0.851
Sparse Partial Least Squares 0.914 0.457 0.371 0.822 0.858 0.694 0.552 0.851
Random Forests 0.872 0.566 0.438 0.810 0.932 0.596 0.528 0.866
Nearest Shrunken Centroids 0.882 0.527 0.409 0.805 0.833 0.643 0.476 0.802
Support Vector Machine 0.806 0.424 0.230 0.680 0.929 0.645 0.574 0.868
Ten statistical machine learning algorithms were used to determine groups of markers capable of distinguishing very mildly/mildly demented (CDR 0.5 and 1 combined)
from cognitively normal participants (CDR 0). Models were fit with two sets of predictors: 1) traditional biomarkers, or 2) traditional biomarkers plus RBM analytes;
additionally, age, gender, and ApoE4 allele status were included in all models. Model performance measures shown are based on cross-validation, in which the test set
results were averaged from 200 splits of the data between training (80%) and test (20%).
doi:10.1371/journal.pone.0018850.t006
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the analysis of larger combinations of markers, multiple machine
learning algorithms likewise showed that the novel biomarkers
improved upon the diagnostic performance of the traditional
biomarkers (Ab42, tau, p-tau181). Importantly, nearly all of the
markers found to best discriminate CDR 0 from CDR 0.5 and 1
participants in the more targeted ROC analyses were also
identified as the top predictors in the machine learning models
that contain a built-in importance statistic (10 of 12 markers).
Thus, the potential of these analytes as biomarkers for AD is
supported by alternative statistical approaches that yielded similar
results. Further supporting these results is a recent report of the
application of a smaller RBM Discovery MAP panel to a smaller
cohort of AD, MCI, and control subjects [18]; this study identified
a number of the same analytes as being differentially expressed in
AD CSF as compared to control CSF and, although using
different analytical approaches, included VEGF, TRAIL-R3, and
eotaxin-3, in ‘combined’ models of novel and traditional
biomarkers.
It is important to note that while the models used in our study
suggest diagnostic value of the novel biomarkers, other combina-
tions of these markers may be optimal; it will be of interest in future
studies to validate the results of this discovery study in additional
cohorts and to determine whether alternative combinations of these
markers may demonstrate improved performance. The levels of at
least 7 of the novel biomarkers have been evaluated in AD subjects
in other studies: no change was observed in plasma PAI-1 levels
[44]; in agreement with our findings, two studies have reported
increased CSF MIF in AD and MCI subjects [45], [46]; also
consistent with our findings, increased fibrinogen levels have been
observed in AD and MCI CSF [47] and in AD plasma [48], and
increased plasma levels have been associated with an increased risk
of future dementia [49]; results have been mixed regarding CSF
FAS levels in AD [50], [51]; AD plasma/serum VEGF levels have
been reported to be unchanged [52], [53], decreased [54], and
increased [55], while CSF levels have been reported to be
unchanged [56] or increased [57]; no change in CSF or serum
levels of TNF RII in AD has been reported [58]; cystatin C findings
have been inconsistent, with reports of serum/plasma levels
unchanged [59], increased in AD [60] or in those who later
develop AD [61], and decreased [62] or decreased levels associated
with increased risk of future AD [63], while CSF levels have been
reported to be unchanged [59], [64], decreased [65], or increased
[21]. These inconsistent results may be due in part to the existence
of a truncated form of cystatin C, which was found to be increased
in AD CSF, while the full length protein was decreased [20], [21].
Furthermore, the potential involvement of each marker in
AD pathophysiology necessitates investigation. The candidate
biomarkers identified in the ROC and machine learning portions
of this study belong to a wide variety of functional classes and
pathways, including tissue remodeling and angiogenesis (MMP-10,
VEGF), regulation of apoptosis (TRAIL-R3, FAS), neutrophil,
eosinophil, and/or basophil chemotaxis (GRO-a, eotaxin-3),
blood coagulation (Fibrinogen, PAI-1), intravascular volume
homeostasis (NT-proBNP), and gastrointestinal and pancreatic
secretions (PP). In addition, a number of molecules involved in
inflammatory pathways were identified in the machine learning
models (IL-7, IL-17E, TNF RII, MCP-2, FASL, MIF). The
association of several of the candidate biomarkers with AD
pathophysiology has already been probed, most notably for
cystatin C, which appears to play a role in preventing Ab
oligomerization and amyloidogenesis [66–70], and to a lesser
extent for PAI-1 [71–73], MIF [45], [74], fibrinogen [75], [76],
FAS and FASL [77–80], VEGF [81–83], and TNF RII [84–86].
It will be important in future studies to assess each candidate
biomarker’s value in diagnosis in independent sample sets when
combined with other existing biomarkers or imaging tools. The
existing gold standard validated biomarkers include CSF tau, p-
tau181, and amyloid imaging, which differ between control and
AD populations and mark underlying AD pathology [4], [6], [31],
[32]. Additionally, to follow up on these biomarker candidates,
their ability to discriminate AD from other causes of dementia
Table 7. Top 15 predictors for machine learning algorithms with a built-in importance measure.
Predictor Boosted Tree Nearest Shrunken Centroids Random Forests Partial Least Squares
1 tau Tau Ab42 Tau
2A b42 Ab42 tau Ab42
3 VEGF p-tau181 MMP-10 VEGF
4 MMP-10 GRO-a KIM-1 p-tau181
5 PP VEGF VEGF GRO-a
6 KIM-1 Eotaxin-3 IL-7 PP
7 Cystatin C Age IL-17E Cystatin C
8 Calbindin PP PP NT-proBNP
9 NT-proBNP Cortisol NT-proBNP MMP-10
10 MIF MCP-2 TRAIL-R3 KIM-1
11 IGFBP-2 TECK p-tau181 Apo A1
12 TRAIL-R3 MMP-10 Cystatin C e3e4
13 FSH IL-17E MIF IL-7
14 FAS IL-7 GRO-a Insulin
15 TNF RII FASL CKMB Age
Ranking of the top 15 predictors for the four models with a built-in importance statistic demonstrates considerable overlap in the top predictors for each model.
Furthermore, nearly all of the markers found to best discriminate CDR 0 from CDR.0 participants in the more targeted ROC analyses (Table 5) were also identified as the
top predictors in the machine learning models, reconfirming their biomarker potential.
doi:10.1371/journal.pone.0018850.t007
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already shown promise for distinguishing AD from frontotemporal
lobar degeneration (cystatin C [20], eotaxin-3 [18], and HGF
[18]). Incorporation of such markers into a biomarker panel may
improve diagnostic specificity. Beyond their clinical use, these
markers may have great value in the design of and enrollment in
trials of disease-modifying therapies. By enrolling only subjects
with lower or higher values of a particular marker (or panels of
markers) indicative of AD, and excluding potential subjects with
intermediate or ‘overlap’ values, one might provide greater
diagnostic certainty than is possible through clinical evaluation
alone. This is especially relevant for the design and evaluation of
primary prevention trials in cognitively normal cohorts. Enriching
study populations for subjects displaying certain biomarker levels
may result in studies of greater efficacy, translating to reduced cost
and duration.
This study also suggests a novel biomarker, CSF calbindin, that
can predict risk of future dementia in individuals who are still
cognitively normal. Previous studies have shown that Ab42, tau,
YKL-40 (an astrocyte marker), and the ratios tau/Ab42 and YKL-
40/Ab42 can predict subsequent cognitive decline in non-
demented cohorts [7], [15], [87]. Using multivariate Cox
proportional hazards models to determine the best combination
of biomarkers for prognosis, we show here that a panel of markers
consisting of calbindin, Ab42, and age has predictive value
comparable to, if not better than, a second panel consisting of tau,
Ab42, and age. Tissue culture studies have shown that increased
expression of calbindin, a calcium binding protein present in
central and peripheral nervous system neurons, correlates with
increased resistance to cell death triggered by a variety of causes,
including exposure to excitatory amino acids, ischemic injury, and
Ab [88–91]. Decreases in calbindin protein and mRNA levels [92]
and number of calbindin-immunopositive neurons [93–95] have
been observed in AD brains compared to controls. Further
suggesting there may be a role for calbindin in AD pathophys-
iology is the large body of literature demonstrating that increased
oxidative stress and altered calcium homeostasis appear to be
interrelated mechanisms in AD pathogenesis. Interestingly,
although not quite reaching statistical significance, we found that
CSF calbindin levels trended higher in the very mildly/mildly
demented group (p=.0660; CDR 0= 145.9 ng/mL, CDR.0=
157.4 ng/mL), suggesting that perhaps degenerating neurons
Table 8. Cox proportional hazards models for predicting risk of developing cognitive impairment (conversion from CDR 0 to
CDR.0).
A. Marker HR 95% CI P
Log Calbindin 1.736 1.161–2.596 0.0072
Log 1/Ab42 2.361 1.564–3.564 ,0.0001
Age 1.094 1.043–1.147 0.0002
Gender 0.722 0.326–1.599 0.4216
B. Marker HR 95% CI P
Log Calbindin 1.752 1.176–2.609 0.0058
Log 1/Ab42 2.485 1.655–3.731 ,0.0001
Age 1.092 1.037–1.149 0.0008
ApoE4 0.847 0.355–2.025 0.7094
C. Marker HR 95% CI P Overall HR 4.704
Log Calbindin 1.750 1.172–2.613 0.0063
Log 1/Ab42 2.454 1.637–3.679 ,0.0001
Age 1.096 1.045–1.149 0.0002
D. Marker HR 95% CI P
Log Tau 1.462 1.039–2.057 0.0294
Log 1/Ab42 2.221 1.477–3.339 0.0001
Age 1.096 1.041–1.154 0.0005
Gender 0.724 0.334–1.566 0.4113
E. Marker HR 95% CI P Overall HR 3.610
Log Tau 1.467 1.046–2.056 0.0262
Log 1/Ab42 2.247 1.496–3.375 ,0.0001
Age 1.098 1.043–1.156 0.0003
Cox proportional hazards models were used to identify panels of biomarkers predictive of the risk of developing cognitive impairment (conversion from CDR 0 to
CDR.0). Analyte measurements were converted to standard Z-scores to allow for comparison of hazard ratios between the different analytes. Variables withp ,0.15 in
the univariate Cox analyses were considered for inclusion in multivariate models; variables were retained in the final model if p,0.05. Because many of the analytes,
including calbindin, demonstrated age and gender affects, both variables were entered into the multivariate models. However, as gender did not appear to contribute
to the models (A, D), it was not included in the final panels (C, E). Similarly, apoE allelic status (E4+ vs. E42) did not contribute to the models (B), and was not included in
the final model (C). Although calbindin and tau both demonstrated p,0.05 in the univariate analyses, the significant correlation between the two (r=0.476, p,0.0001)
prohibited inclusion of both variables in the multivariate model. Therefore, a separate multivariate model that included tau was evaluated (D, E). The higher HR of
calbindin than of tau, and the higher overall HR (4.704.3.610) and lower AIC (227.6,230.8) of the first model support it as the better model.
doi:10.1371/journal.pone.0018850.t008
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findings of a small study of 6 AD brains suggesting that
calbindin-immunopositive neurons are relatively preserved in
cases with moderate amyloid plaque and neurofibrillary content
but are lost in more severe cases [94] prompts the question of
whether CSF calbindin levels would be more significantly elevated
in more severely demented individuals. Further studies are needed
to confirm the prognostic potential of CSF calbindin, to determine
if other complementary fluid or imaging biomarkers may improve
upon its performance, and to more definitively elucidate its role in
AD pathophysiology. As with the candidate diagnostic biomarkers,
CSF calbindin may have value for clinical trial design by allowing
for the selective enrollment of individuals who are at greater risk of
developing cognitive impairment, resulting in clinical trials of
shorter duration and reduced cost.
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